Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

  • In development
  • GID-TA11662
  • Expected publication date: 

Suggested remit: To appraise the clinical and cost effectiveness of Budesonide within its marketing authorisation for treating IgA nephropathy